La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Alnylam Pharmaceuticals Gestione
Gestione criteri di controllo 3/4
Alnylam Pharmaceuticals' Il CEO è Yvonne Greenstreet, nominato in Jan2022, e ha un mandato di 2.58 anni. la retribuzione annua totale è $ 8.90M, composta da 11% di stipendio e 89% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.039% delle azioni della società, per un valore di $ 13.44M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.1 anni e 8.8 anni.
Informazioni chiave
Yvonne Greenstreet
Amministratore delegato
US$8.9m
Compenso totale
| Percentuale dello stipendio del CEO | 11.0% |
| Mandato del CEO | 2.6yrs |
| Proprietà del CEO | 0.04% |
| Durata media del management | 3.1yrs |
| Durata media del Consiglio di amministrazione | 8.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results
Aug 04
Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher
Aug 02RNAi: Winning In The Clinic, Now For The Market
Jun 25Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
Jun 03Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking
Mar 19Is Alnylam's HELIOS-B Delay A Red Flag?
Mar 10Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think
Feb 18Alnylam's Huge Opportunity
Jan 12Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues
Dec 18Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares
Jun 23Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?
Oct 25Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo
Oct 07Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market
Sep 26Alnylam RNAi therapy for rare protein disorder gets EU approval
Sep 20Alnylam to offer $900M convertible senior notes
Sep 12Alnylam says trial of RNAi therapeutic cemdisiran achieves goals for IgA nephropathy
Aug 29Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$73m |
| Mar 31 2024 | n/a | n/a | -US$332m |
| Dec 31 2023 | US$9m | US$976k | -US$440m |
| Sep 30 2023 | n/a | n/a | -US$510m |
| Jun 30 2023 | n/a | n/a | -US$1b |
| Mar 31 2023 | n/a | n/a | -US$1b |
| Dec 31 2022 | US$5m | US$850k | -US$1b |
| Sep 30 2022 | n/a | n/a | -US$1b |
| Jun 30 2022 | n/a | n/a | -US$981m |
| Mar 31 2022 | n/a | n/a | -US$893m |
| Dec 31 2021 | US$9m | US$619k | -US$853m |
| Sep 30 2021 | n/a | n/a | -US$838m |
| Jun 30 2021 | n/a | n/a | -US$887m |
| Mar 31 2021 | n/a | n/a | -US$876m |
| Dec 31 2020 | US$3m | US$622k | -US$858m |
| Sep 30 2020 | n/a | n/a | -US$891m |
| Jun 30 2020 | n/a | n/a | -US$846m |
| Mar 31 2020 | n/a | n/a | -US$886m |
| Dec 31 2019 | US$3m | US$571k | -US$886m |
| Sep 30 2019 | n/a | n/a | -US$821m |
| Jun 30 2019 | n/a | n/a | -US$858m |
| Mar 31 2019 | n/a | n/a | -US$802m |
| Dec 31 2018 | US$3m | US$540k | -US$761m |
| Sep 30 2018 | n/a | n/a | -US$692m |
| Jun 30 2018 | n/a | n/a | -US$570m |
| Mar 31 2018 | n/a | n/a | -US$525m |
| Dec 31 2017 | US$985k | US$504k | -US$491m |
Compensazione vs Mercato: La retribuzione totale di Yvonne ($USD 8.90M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 13.21M ).
Compensazione vs guadagni: La retribuzione di Yvonne è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Yvonne Greenstreet (61 yo)
2.6yrs
Mandato
US$8,895,670
Compensazione
Dr. Yvonne L. Greenstreet, MBChB, MBA, is Chief Executive Officer at Alnylam Pharmaceuticals, Inc. since January 01, 2022. Dr. Greenstreet joined the Alnylam Pharmaceuticals, Inc. on September 19, 2016. Sh...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 2.6yrs | US$8.90m | 0.039% $ 14.0m | |
| CFO & Executive VP | 5yrs | US$3.22m | 0.017% $ 5.9m | |
| Chief Innovation Officer & Member of the Scientific Advisory Board | less than a year | US$3.32m | 0.018% $ 6.5m | |
| Chief Medical Officer | 9.8yrs | US$3.23m | 0.0090% $ 3.2m | |
| Executive VP & Chief Commercial Officer | 3.6yrs | US$2.87m | 0.0054% $ 1.9m | |
| Chief Technical Operations & Quality Officer | 1.6yrs | Nessun dato | Nessun dato | |
| Senior VP | 5.3yrs | Nessun dato | 0.010% $ 3.7m | |
| Senior VP of Investor Relations & Corporate Communications | no data | Nessun dato | Nessun dato | |
| Chief Ethics & Compliance Officer | 1.9yrs | Nessun dato | Nessun dato | |
| Chief Corporate Development & Strategy Officer | 1.9yrs | Nessun dato | Nessun dato | |
| Chief Human Resource Officer | 5.3yrs | Nessun dato | Nessun dato | |
| Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato |
3.1yrs
Durata media
56yo
Età media
Gestione esperta: Il team dirigenziale di ALNY è considerato esperto (durata media dell'incarico 3.1 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 2.8yrs | US$8.90m | 0.039% $ 14.0m | |
| Chief Innovation Officer & Member of the Scientific Advisory Board | no data | US$3.32m | 0.018% $ 6.5m | |
| Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board | 8.8yrs | Nessun dato | Nessun dato | |
| Independent Director | 1.4yrs | US$658.72k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | US$516.04k | Nessun dato | |
| Independent Director | 8.7yrs | US$477.21k | 0.022% $ 7.8m | |
| Co-Founder | 22.2yrs | US$502.21k | 0.21% $ 74.5m | |
| Independent Chair of the Board & Lead Independent Director | 10.1yrs | US$531.36k | 0.0066% $ 2.4m | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of the Scientific Advisory Board & Independent Director | 12.3yrs | US$477.21k | 0.0028% $ 1.0m | |
| Independent Director | 6.2yrs | US$489.15k | 0% $ 0 |
8.8yrs
Durata media
69.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ALNY sono considerati esperti (durata media dell'incarico 8.8 anni).